Cook Medical led the series D financing, and also signed up to exclusively distribute the minimally invasive nitinol implant, which is designed to re-open a urethra blocked by an enlarged prostate through a reversible approach.
Additional funds came from first-time backer ClavystBio, alongside returning investors in Invus Opportunities, F-Prime, Medtech Venture Partners and more. The round also included debt financing from HSBC and Trinity Capital.
Cook Medical previously invested in Zenflow in a 2024 series C, pitching the Spring system as a potential first-line intervention that can be used for BPH symptoms ahead of drug therapies or surgery.
Approved by the FDA late last year, the coil-like implant can be delivered without general anesthesia or incisions, and includes multiple sizes with a single-use, flexible cystoscope and integrated positioning balloon.
“Cook Medical’s deep relationships within urology and proven commercialization capabilities make them the ideal partner to help bring the benefits of the Zenflow Spring to patients across the country,” said Zenflow CEO Shreya Mehta. “We are thrilled to close this round of financing, demonstrate our commercial potential, and help physicians treat many more patients.”
Earlier this year, Zenflow reported clinical data showing its Spring implant could deliver 37% improvements on the international Prostate Symptom Score metric, with a low rate of complications.
“Our initial investment in Zenflow reflected our confidence in both the technology and the team,” said DJ Sirota, senior VP of Cook Medical’s medical surgical division. “Today, we are proud to deepen that commitment with a substantial Series D investment and to take on the role of sole U.S. distributor for the Zenflow Spring.”
“BPH is one of the most prevalent conditions affecting men’s quality of life, and yet many patients remain undertreated or dissatisfied with existing options,” added Johan Lowinger, director of product management for Cook Medical’s urology specialty. “The Zenflow Spring represents exactly the kind of breakthrough we look for — a simple, effective, office-based solution that puts patients first.”
Around the same time as Spring’s December 2025 approval, the FDA also handed a green light to ProVerum for its ProVee nitinol stent for BPH. That Dublin, Ireland-based company raised $80 million last year to support its development and launch.
